LT4/LT3 Combination Therapy Versus LT4 Monotherapy in Patients with Autoimmune Hypothyroidism.

PHASE3RecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

October 7, 2022

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Autoimmune Hypothyroidism
Interventions
DRUG

LT3 (liothyronine)

Addition of liothyronine (LT4/LT3 combination therapy) in patients with persistent tiredness on LT4 monotherapy. To investigate whether addition of LT3 is effective in relieving tiredness.

DRUG

Placebo

Addition of placebo (LT4 monotherapy) in patients with persistent tiredness on LT4 monotherapy.

Trial Locations (19)

Unknown

RECRUITING

Flevoziekenhuis, Almere Stad

RECRUITING

Amsterdam UMC - Location AMC, Amsterdam

NOT_YET_RECRUITING

Gelre ziekenhuizen, Apeldoorn

RECRUITING

Rijnstate, Arnhem

RECRUITING

Amphia ziekenhuis, Breda

RECRUITING

Van Weel-Bethesda Hospital, Dirksland

RECRUITING

Albert Schweitzer Hospital, Dordrecht

NOT_YET_RECRUITING

Treant, Emmen

RECRUITING

Admiraal de Ruyter Hospital, Goes

RECRUITING

University Medical Center Groningen, Groningen

RECRUITING

Saxenburgh MC, Hardenberg

RECRUITING

Radboudumc, Nijmegen

RECRUITING

Erasmus Medical Center, Rotterdam

RECRUITING

Maasstad Hospital, Rotterdam

RECRUITING

Franciscus Gasthuis & Vlietland, Schiedam

RECRUITING

Zuyderland, Sittard

RECRUITING

University Medical Center Utrecht, Utrecht

RECRUITING

Maxima Medical Center, Veldhoven

NOT_YET_RECRUITING

Vie Curie MC, Venlo

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

ACE Pharmaceuticals BV

OTHER

lead

M. Medici

OTHER